In vivo characterization of the human glioblastoma infiltrative edge with label-free intraoperative fluorescence lifetime imaging.
Alba Alfonso-GarciaSilvia Noble AnbunesanJulien BecHan Sung LeeLee-Way JinOrin BlochLaura MarcuPublished in: Biomedical optics express (2023)
Challenges in identifying a glioblastoma's infiltrative edge during neurosurgical procedures result in rapid recurrence. A label-free fluorescence lifetime imaging (FLIm) device was used to evaluate glioblastoma's infiltrative edge in vivo in 15 patients (89 samples). FLIm data were analyzed according to tumor cell density, infiltrating tissue type (gray and white matter), and diagnosis history (new or recurrent). Infiltrations in white matter from new glioblastomas showed decreasing lifetimes and a spectral red shift with increasing tumor cell density. Areas of high versus low tumor cell density were separated through a linear discriminant analysis with a ROC-AUC=0.74. Current results support the feasibility of intraoperative FLIm for real-time in vivo brain measurements and encourage refinement to predict glioblastoma infiltrative edge, underscoring the ability of FLIm to optimize neurosurgical outcomes.
Keyphrases
- label free
- white matter
- single cell
- cell therapy
- high resolution
- end stage renal disease
- endothelial cells
- ejection fraction
- patients undergoing
- chronic kidney disease
- type diabetes
- prognostic factors
- adipose tissue
- peritoneal dialysis
- single molecule
- newly diagnosed
- stem cells
- mesenchymal stem cells
- metabolic syndrome
- insulin resistance
- patient reported outcomes
- fluorescence imaging
- quantum dots
- blood brain barrier
- weight loss
- sensitive detection